Abstract: Methods for producing megakaryocytic progenitors (preMKs) and megakaryocytes (MKs) from stem cells are provided. The present disclosure further provides compositions comprising preMKs and MKs and their lysates, and also methods of use of preMKs, MKs, their lysates and compositions thereof.

Abstract: The instant disclosure provides a system comprising a plurality of stacked bioreactors, wherein the system is configured to provide a substantially equal flow rate of fluid and pressure drop through each of the plurality of bioreactors. In some embodiments, the flow of the fluid through each of the plurality of bioreactors is configured to generate physiological shear rates to induce a biological source material in the bioreactors to produce target biological products.

Abstract: Methods for producing megakaryocytic progenitors (preMKs) and megakaryocytes (MKs) from stem cells are provided. The present disclosure further provides compositions comprising preMKs and MKs and their lysates, and also methods of use of preMKs, MKs, their lysates and compositions thereof.

Abstract: A bioreactor including a bioreactor body, wherein the bioreactor body includes a first substrate and an opposing second substrate, a pathway extending through the bioreactor body and being formed by a first channel defined in the first substrate and an opposing second channel defined in the second substrate, a first inlet for introducing a first fluid flow to the first channel, a second inlet for introducing a second fluid flow to the second channel, a first outlet for permitting the first fluid flow to exit the first channel, a second outlet for permitting the second fluid flow to exit the second channel, a membrane disposed in the pathway between the first and second channels and having a plurality of pores sized to selectively capture, in the first channel, a biological source material and to permit biological products to be collected from the bioreactor.

Abstract: The present disclosure provides methods for generating megakaryocytes and novel platelet variants from the same CD34+ progenitor stem cells, which comprises at least two stages: stage zero (0) comprising an expansion and maintenance stage of the CD34+ progenitor stem cells for a period ranging between 0 hours to 48 hours; and, stage one (I) comprising a differentiation phase wherein the differentiation phase comprises differentiating the CD34+ progenitor stem cells in step (i) for a period sufficient to generate substantially matured megakaryocytes. Novel platelet variants are produced by passaging the megakaryocytes, produced by the CD34+ progenitor stem cells, through a bioreactor or a fluidic device. Formulations comprising megakaryocytes and platelet variants derived from CD34+ progenitor stem cells and methods of their use are also disclosed.

Abstract: Described herein are methods for treating, repairing or ameliorating diseases, disorders, or injuries related to dry eye, osteoarthritis, tendon, ligament, bone repair, wound healing or wound-healing related disorders, alopecia or in skin rejuvenation or regeneration with platelet-like-cells or variants thereof (PLCs) or derivatives thereof or lysates thereof or the platelet rich plasma (PRP) derived therefrom. Also, described herein are methods for generating platelet rich plasma (PRP) from the PLCs or derivatives thereof or lysates thereof.